This phase II trial is testing an oral anti-cancer therapy (Brigatinib) in patients who have ALK+ non-small cell lung cancer.
This trial is treating patients with non-small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Participants in this trial will receive 90mg Brigatinib tablets, once a day for seven days, followed by 180mg Brigatinib tablets once a day until disease progression, as advised by the investigator, or toxicity occurs.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More